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ABSTRACT
Chronic hepatitis B (CHB) is increasingly recognized as a public health problem 
in Taiwan. After affected patients are diagnosed with contaminant liver cirrhosis 
(LC), adverse clinical outcomes, especially death, are common. This study aimed 
to investigate the effect of Chinese herbal medicine (CHM), an essential branch of 
Traditional Chinese medicine (TCM), on the mortality risk among CHB patients with 
contaminant LC. This longitudinal cohort study used the Taiwanese National Health 
Insurance Research Database to identify 1522 patients 20–70 years of age with 
newly diagnosed CHB with LC during 1998–2007. Among them, 508 (33.37%) had 
received CHM products after the onset of CHB (CHM users), and the remaining 1014 
patients (66.63%) were designated as a control group (non-CHM users). All enrollees 
were followed until the end of 2012 to determine deaths during the study period. We 
applied the Cox proportional hazards regression model to compute the hazard ratio 
for the association of CHM use and the subsequent risk of death. During the follow-up 
period, 156 CHM users and 493 non-CHM users died. After controlling for potential 
confounders, CHM users were found to have a significantly reduced risk of death 
compared with non-CHM users by 56%, and the effect was predominantly observed 
among those treated with CHM for > 180 days. CHM therapy lowered the risk of death 
among CHB patients with contaminant LC, which supported CHM might provide further 
treatment options for those with chronic liver diseases.
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INTRODUCTION
Ascites, hepatic encephalopathy, and esophageal 
variceal bleeding are the 3 major complications of 
cirrhosis. The presence of these complications is a sign 
of decompensated liver cirrhosis and usually indicates a 
poor prognosis. In Taiwan, the most common etiology 
of liver cirrhosis is chronic hepatitis B (CHB) [1, 2], and 
most hepatitis B virus (HBV) infections occur following 
vertical transmission. In recent decades, despite the 
improvement of antiviral therapy, the burden of viral 
hepatitis has remained considerable. For example, 
Stanaway and colleagues indicated that the number of 
deaths worldwide attributable to viral hepatitis increased 
from 0.89 million deaths, in 1990, to 1.45 million deaths 
in 2013, an increase of 63% [3], suggesting that HBV 
places a tremendous burden on patients, their families, and 
the healthcare system.
Chinese herbal medicine (CHM) is the most 
commonly used alternative medicine for patients with 
chronic diseases, and several investigators suggested 
that this approach could improve clinical outcomes or 
quality of life. A recent 15-year cohort study of 112,458 
patients with vertigo showed that those receiving CHM 
had a significantly lower risk (36%) of stroke than did 
those who did not receive CHM [4]. Another randomized 
controlled trial conducted among 352 individuals with 
chronic obstructive pulmonary disease compared the 
effectiveness of combining conventional Western medicine 
and several Chinese herbal products for 1 year [5], and 
reported that integrating CHM and Western medicine 
significantly improved pulmonary function, quality of 
life, and psychological health (mood and depression). 
Additionally, in a prior study, we found that the use of 
CHM was associated with a significantly reduced risk of 
hepatocellular carcinoma (HCC) in patients with CHB 
[6]. These findings indicated that the integration of CHM 
into allopathic clinical practice is likely to contribute to 
favorable outcomes.
We conducted a comprehensive literature review 
and discovered that no studies have been reported that 
identified the effect of CHM on the risk of mortality for 
CHB patients with concurrent liver cirrhosis (LC). Given 
that the liver disease is widespread in Taiwan, to prevent 
the corresponding damages, the investigation of the long-
term effect of alternative treatments, specifically CHM, 
for the affected patients is important. More specifically, 
this study aimed to identify the effect of CHM on the 
risk of morality among CHB patients using a nationwide 
population-based database.
RESULTS
We identified 1522 patients with CHB and 
contaminant LC between 1998 and 2007. Of these, 508 
received CHM and 1014 were non-CHM users. Table 1 
shows the basic characteristics of the 2 groups. Compared 
with non-CHM users, those who received CHM services 
were more likely to be female and younger (< 50 years), 
and to have a lower score of Charlson Comorbidity Index 
(CCI) (all P < 0.01) (Table 1).
Among all eligible subjects, 649 deaths occurred, 
including 493 non-CHM users and 156 CHM users, during 
the follow-up periods of 3997.98 and 3644.58 person–
years (PY), respectively. The mortality rate was lower 
in CHM users than in non-CHM users (42.80 vs 123.31, 
respectively, per 1000 PY), with an adjusted hazard ratio 
[3] of 0.44 (95% confidence interval [CI]: 0.36–0.52) 
(Table 2). Of note, patients who used CHM treatments 
for > 180 days had a 67% decreased risk of death (95% 
CI: 0.25–0.42). Based on the Kaplan–Meier survival 
curve and log-rank test results, a statistically significant 
difference regarding the survival rate was observed across 
the 3 groups during the 15-year follow-up period. Those 
who received CHM treatments for > 180 days had a 
significantly lower mortality rate than those who did not 
receive CHM (P < 0.001) (Figure 1).
Table 3 presents results from an analysis that 
stratified patients by age and sex. We found that females 
who received CHM had a lower mortality rate than did 
their non-CHM counterparts (27.10 vs 105.29 per 1000 
PY, respectively), representing a covariate-adjusted 
HR of 0.30 (95% CI: 0.20–0.45). The magnitude of the 
association was statistically significant for male patients, 
who had an adjusted HR of 0.48 (95% CI: 0.39–0.58). 
Furthermore, the effect of CHM in reducing the risk of 
mortality was more prominent for females aged > 50 years 
(adjusted HR: 0.28; 95% CI: 0.17–0.44) (Table 3).
The most commonly prescribed CHMs for patients 
with CHB and contaminant LC are summarized in Table 4. 
Among these products, ten formulae were found to lessen 
the subsequent risk of death, including Dan-shen, Yan-
Hu-Suo, Bei-mu, Huang-Qin, Bie-Chia, Jia-Wei-Xiao-
Yao-San, Xiao-Chai-Hu-Tang, Shu-Jing-Huo-Xue-Tang, 
Chai-Hu-Shu-Gan-Tang, and Long-Dan-Xie-Gan-Tang.
DISCUSSION
Hepatic encephalopathy, ascites, and esophageal 
variceal bleeding are 3 major cirrhosis-related 
complications. In clinical practice, the presence of any 
of these complications is associated with decompensated 
LC and is commonly predictive of a poor prognosis, 
such as death [3]. Therefore, identifying alternative 
treatments that can delay the progression of liver 
disease is important in the prevention of deaths among 
CHB patients with LC. In this study, we employed a 
nationwide population-based database to investigate 
the effect of CHM on the morality risk among these 
patients. To increase the diagnostic accuracy for patients 
who were diagnosed with CHB together with LC, all 
patients in our study were identified based on ICD-9-
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CM codes and if they applied for catastrophic illness 
certificate (CIC) card due to decompensated LC. This 
approach robustly increases the diagnostic accuracy of 
cirrhotic patients.
The effects of antiviral treatment for patients with 
CHB are well established [7, 8]. In this study, we further 
discovered that using CHM therapy during the standard 
antiviral treatment of CHB-related decompensated LC 
can lower the risk of mortality by 56%, which revealed 
the positive association of CHM and lowered risk of 
death among decompensated cirrhotic patients. Current 
medical guidelines have, in the past, been unsupportive 
of using CHM for CHB-related decompensated cirrhotic 
patients. However, over the past decade, certain CHM 
products have been commonly used for treating various 
illnesses [4–6]. A previous study conducted in Taiwan 
reported that the overall prevalence of insurance-covered 
traditional Chinese medicine (TCM) use in patients with 
liver cancer was as high as 21% [9]. In our previous 
study, we found that CHM users had a significantly 
lower HCC risk (37%) compared with non-CHM 
users [6]. LC involves a loss of normal liver structure 
Table 2: Crude and adjusted HR of HCC for CHB patients with and without CHM usage
Patient group Event PY Incidence Crude HR(95% CI) Adjusted HR*(95% CI)
CHM nonusers 493 3997.98 123.31 1 1
CHM users 156 3644.58 42.80 0.35 (0.33–0.46) 0.44 (0.36–0.52)
  CHM use within 30–180 
days 94 1623.47 57.90 0.47 (0.41–0.64) 0.56 (0.45–0.70)
  CHM use lasted for > 
180 days 62 2021.11 30.68 0.25 (0.21–0.35) 0.33 (0.25–0.42)
Incidence rate is per 1000 PY.
*Model adjusted for age, sex, urbanization level, monthly income, and CCI scores.
Table 1: Demographic data and comorbidity comparisons
Variables 
CHM nonusers CHM users
P 
(n = 1014) (n = 508)
Age, (years)   0.003
  ≤ 50 461 (45.5) 255 (50.2)  
  50 553 (54.5) 253 (49.8)  
 Mean (Standard 
Deviation) 51.3 (11.1) 49.6 (11.2)  
Sex   0.001
 Female 251 (24.8) 166 (32.7)  
 Male 763 (75.2) 342 (67.3)  
Monthly income   0.27
 Low 382 (37.7) 182 (35.8)  
 Median 563 (55.5) 280 (55.1)  
 High 69 (6.8) 46 (9.1)  
Residential area   0.93
 Urban 560 (55.2) 277 (54.5)  
 Suburban 166 (16.4) 82 (16.1)  
 Rural 288 (28.4) 149 (29.3)  
CCI   < 0.001
 Mean (SD) 19.73 (19.2) 15.30 (16.2)  
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that interrupts the normal blood flow in the liver and 
progresses to the nodules of the liver, thus resulting in 
functional failure [10]. We inferred that the possible 
pharmacologic mechanisms by which CHM treatment 
acts on CHB patients with LC includes antiviral effects 
[11], potent antioxidant activity, inhibition of free-
radical–induced hepatic fibrosis by reducing cytochrome 
C [12], decreasing HBx-associated pathways [13], and 
modifying the microenvironment of HCC [14]. These 
effects of CHM treatments may contribute to the 
alleviation of liver fibrosis and cirrhosis.
Figure 1: Survival rate according to TCM use status, all-cause mortality. P is based on the log-rank test across 3 groups.
Table 3: Age- and sex-specific incidence and adjusted HR of death in relation to CHM among CHB patients 
with LCC
Variables 
CHM nonusers CHM users  
Crude HR (95% CI) Adjusted HR (95% CI) 
Case PY Incidence Case PY Incidence
Female         
  ≤ 50 24 475.39 50.48 8 647.20 12.36 0.26 (0.12–0.58) 0.41* (0.17–0.75)
  50 82 531.34 154.33 26 607.35 42.81 0.28 (0.18–0.45) 0.28* (0.17–0.44)
 All 106 1006.73 105.29 34 1254.55 27.10 0.26 (0.18–0.41) 0.30ƪ (0.20–0.45)
Male         
  ≤ 50 165 1598.62 103.21 57 1378.04 41.36 0.40 (0.34–0.63) 0.48* (0.35–0.61)
 > 50 222 1392.63 159.41 65 1011.99 64.22 0.38 (0.35–0.59) 0.47* (0.35–0.60)
 All 387 2991.25 129.38 122 2390.03 51.04 0.39 (0.36–0.55) 0.48ƪ (0.39–0.58)
Incidence rate is per 1000 PY.
*Model adjusted for urbanization level, monthly income, and CCI scores.
ƪ Model adjusted for age, urbanization level, monthly income, and CCI scores.
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Table 4: Risk of death in relation to the top 10 used single herb and multi herb products for CHB patients with 
contaminant LC
Chinese herbal 
name
Scientific 
name
Frequency of 
prescriptions
Average 
duration (day)
Daily dose (g) Crude HR 
(95% CI)
Adjusted HR* 
(95% CI)
Single-herb 
products       
Dan-shen
Salvia 
miltiorrhiza 
Bunge., 
Rhizoma
19786 9.3 10.59 0.36(0.31-0.42) 0.34(0.29-0.40)
Yan-Hu-Suo
Corydalis 
yanhusuo W.T. 
Wang, Rhizoma
5915 9.2 10.62 0.28(0.20-0.39) 0.29(0.21-0.42)
Hai-Piao-Xiao
Endoconcha 
Sepiae, 
Cuttlefish Bone
3848 7.03 9.11 0.42(0.27-1.03) 0.46(0.30-1.05)
Bei-mu
Fritillaria 
thunbergii Miq., 
Balbus
3707 11.21 8.98 0.21(0.13-0.34) 0.22(0.13-0.35)
Huang-qi
Astragalus 
membranaceus 
(Fisch.) Bunge, 
Rhizoma
3616 13.42 17.73 0.40(0.12-1.09) 0.42(0.13-1.06)
Yu-Jin
Curcuma 
aromatica 
Salisb., 
Rhizoma
2959 7.69 7.42 0.38(0.04-1.02) 0.37(0.03-1.01)
Bai-Hua-She-
She-Cao
Hedyotis 
diffusissima 
Merr., Herba
3384 12.00 16.10 0.49(0.19-1.22) 0.48(0.18-1.25)
Ge-gen
Pueraria lobata 
(Willd.) Ohwi, 
rhizoma
3412 8.35 9.76 0.42(0.11-1.20) 0.41(0.09-1.27)
Huang-Qin
Scutellaria 
baicalensis 
Georgi, 
Rhizoma
3374 7.47 8.80 0.19(0.12-0.30) 0.20(0.12-0.29)
Bie-Chia
Pelodiscus 
sinensis, soft-
shelled turtle
2511 10.51 15.88 0.17(0.11-0.26) 0.18(0.12-0.27)
Multi-herb 
products       
Jia-wei-Xiao-
Yao-San  6064 10.43 16.93 0.25(0.19-0.36) 0.26(0.18-0.36)
Xiao-Chai-Hu-
Tang  4161 9.66 14.80 0.27(0.18-0.41) 0.27(0.19-0.40)
Shu-Jing-Huo-
Xue-Tang  5297 7.47 11.92 0.22(0.15-0.33) 0.21(0.14-0.32)
(Continued)
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In addition, results from our study indicate that 
elderly patients benefited the most from CHM in terms 
of reduced risk of death. No previous studies have been 
conducted to determine the long-term effect of CHM on 
the risk of death among CHB patients with contaminant 
LC, which precludes a comparison of results. Yet, 
several possible explanations may clarify these observed 
differences: First, the number of younger patients in our 
study was smaller, and the rates at which they developed 
adverse outcomes were somewhat lower than those of the 
older patients. Second, according to a previous study of 
the natural history of patients with CHB in Taiwan, the 
reported risk of LC in patients with CHB begins to rise 
during the patients’ 40s and increases significantly after 
age 50 [15]. Additionally, during 2000-2015, the death 
rates associated with LC in the US population increased 
21% for men and 57% for women among persons aged 
45–64 years [16]. Thus, the probability that LC risk 
increases with advanced age may explain the significant 
effect of CHM among elderly patients.
The present study has also listed the most commonly 
prescribed single herb and multi herb products in treating 
CHB patients with contaminant LC. Among the commonly 
prescribed multi-herb products, we noted that Jia-wei-
Xiao-Yao-San (JWXYS) plays a role in lowering the risk 
of death. It could be argued that JWXYS which exhibits 
potent antioxidant activity and inhibits free-radical-
induced hepatic fibrosis by cytochrome C reduction 
[12], also contributes to better prognosis for liver cancer 
patients. Chai-Hu-Shu-Gan-Tang (CHSGT) was also 
found to be significantly related to lower risk of death. 
We speculate that this herb could soothe the liver and 
disperse the stagnated liver Qi. It should be noted that the 
positive therapeutic effects derived from the components 
of CHSGT, such as Chai-Hu, Shao-Yao, Gan-Cao and 
Chuan-Xiong), were found to be identical to those of 
Si-Ni-San (SNS). Our previous study showed that SNS 
suppresses the HBx-induced invasiveness and metastatic 
potential of hepatocellular carcinoma cells [13]. This 
finding also suggests that CHSGT may reduce subsequent 
risk of death among the affected patients.
Another herbal formula that possesses liver 
protection, Xiao-Chai-Hu-Tang (XCHT), has been 
widely used in Asian to treat chronic viral liver diseases 
[6, 17, 18]. Chai-Hu (Bupleurum chinense) and Huang-
qin (Scutellaria baicalensis) are two of the ingredients 
of XCHT. Saikosaponin-A is extracted from bupleurum, 
which acts as an antioxidant and suppresses inflammation 
and fibrogenesis [19]. Furthermore, several reports 
demonstrated that Scutellaria baicalensis and baicalein 
have anti-fibrotic effects on rat liver [20–22]. The 
beneficial effect of Long-Dan-Xie-Gan-Tang (LDXGT) in 
lowering risk of death was also found in the present study. 
This herbal product has been proven to decrease the serum 
lactate dehydrogenase (LDH) and ALT levels following 
liver injury and further reduce the cell degeneration and 
liver necrosis induced by CCl4, which in turn improves 
the biotransformation function of the liver [23]. A further 
finding indicated that Shu-Jing-Huo-Xue-Tang (SJHXT) 
was related to lower risk of death. The likely explanation 
for this finding is that SJHXT may have lessened the 
deterioration of hepatic injury by improving blood 
circulation and reducing the blood stasis syndrome [24].
Additionally, we also observed that those who used 
Yan-hu-suo were at a lower risk of death. This product is a 
well-known traditional CHM that was used for those with 
hepatitis or liver cirrhosis and acts to strengthen the immune 
system and to attenuate the pain sensory due to qi stagnation 
Chinese herbal 
name
Scientific 
name
Frequency of 
prescriptions
Average 
duration (day)
Daily dose (g) Crude HR 
(95% CI)
Adjusted HR* 
(95% CI)
Chai-Hu-Shu-
Gan-Tang  3309 10.38 21.53 0.20(0.13-0.34) 0.22(0.13-0.35)
Ping-Wei-San  4803 8.22 16.85 0.50(0.30-1.45) 0.49(0.33-1.41)
Long-Dan-Xie-
Gan-Tang  2864 8.25 15.01 0.31(0.21-0.48) 0.35(0.23-0.53)
Shao-Yao-Gan-
Cao-Tang  3952 7.09 16.04 0.39(0.10-1.08) 0.41(0.13-1.12)
Xiang-Sha-Liu-
Jun-Zi-Tang  3935 7.47 10.68 0.42(0.14-1.34) 0.46(0.15-1.36)
Yin-Chen-Wu-
Ling-San  2603 6.88 11.26 0.36(0.10-1.01) 0.39(0.11-1.09)
Xue-Fu-Zhu-
Yu-Tang  2697 7.44 11.55 0.34(0.08-1.11) 0.36(0.09-1.18)
*Model adjusted for age, gender, urbanization level, monthly income, and CCI scores.
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[25]. Another commonly used single drug prescription, Bei 
Mu, has been integrated into some Chinese herb formulae 
for treating cancer patients. The alkaloid verticinone, 
derived from Bei Mu, could exert an antinociceptive and 
anti-inflammatory effects on cancer-related neuropathic 
pain through both peripheral and central actions [26], which 
may enhance hepatoprotective activity.
Despite the clinical and research implications 
suggested by the present study, there are several 
limitations to consider. First, although the severity of 
LC was commonly based on the Child–Pugh score, 
it was difficult to identify the laboratory data or viral 
load in this database. Second, we identified patients 
with CHB and liver cirrhosis using ICD-9-CM codes, 
and misclassification may be possible. To decrease 
the possibility of this error, we selected patients with 
CHB only after they were recorded as having at least 3 
outpatient visits that reported consistent diagnoses, or 
at least one inpatient admission. Otherwise, all patients 
with decompensated LC received a CIC from the National 
Health Insurance (NHI) program in Taiwan. For these 
patients, the diagnosis of decompensated LC was double-
checked, which made the diagnosis of LC in this study 
more reliable. Third, during this study period, high-
potency antiviral treatments for CHB such as entecavir or 
tenofovir were not widely used in Taiwan. However, this is 
the first nationwide population-based study that identifies 
the effect of CHM on the mortality rates of patients with 
CHB-related decompensated LC. Further study may be 
needed to more carefully evaluate the effects of CHM for 
patients with CHB-related cirrhosis, in particular if they 
also concurrently receive high-potency drugs. Fourth, 
evidence derived from any observational cohort study is 
generally less robust than data obtained from randomized 
trials because cohort study designs are subject to various 
biases, including confounding effects. Further research 
focusing on possible confounders identified in the 
literature are warranted to fully clarify the impact of CHM 
on the psychosocial health, especially on the patient’s 
quality of life.
In conclusion, the use of CHM was associated 
with a significantly improved survival rate among CHB-
related decompensated LC patients. The results of our 
study provide strong evidence for health care providers to 
consider the use of CHM therapy to improve the survive 
of patients with CHB-related decompensated LC.
Figure 2: Flowchart of selection and follow-up of study subjects.
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MATERIALS AND METHODS
Data source
The NHI program of Taiwan was launched in 
1995 and offers coverage to approximately 99% of the 
nation’s population of 25 million [27]. For research and 
administrative purposes, the Taiwanese National Health 
Research Institute used these claims data to establish 
various database sets for public use. This retrospective 
cohort study used the Longitudinal Health Insurance 
Database (LHID) that comprises claims data for 1 million 
beneficiaries randomly sampled from the registry for 
beneficiaries of the National Health Insurance Research 
Database. Because a multistage stratified systematic 
sampling method was used, no statistically significant 
differences were observed in age, sex, or average salary 
between the sample group and all enrollees in the NHI 
program [27]. This dataset contains information about all 
medical services, such as ambulatory care claims, inpatient 
claims, prescription drugs, and claimed medical expenses. 
To date, > 300 published scientific papers have been based 
on this database [28].
This study was conducted in accordance with 
the Helsinki Declaration, and it was also evaluated and 
approved by the local Institutional Review Board and 
Ethics Committee of Buddhist Dalin Tzu Chi Hospital, 
Taiwan (No. B10004021-1). Because the LHID files 
contain only de-identified secondary data, the review 
board waived the requirement for obtaining informed 
consent from the patients.
Study population
The participant selection process is shown in Figure 
2. All diagnoses in this insurance claims dataset were 
coded using the International Classification of Disease, 
9th Revision, Clinical Modification (ICD-9-CM). With it, 
we identified patients 20–to-70 years of age with newly 
diagnosed CHB during 1998–2007 (ICD-9-CM codes: 
070.2, 070.3, or V02.61) and treatment with nucleos(t)ide 
analogues (lamivudine, adefovir, telbivudine, entecavir, or 
tenofovir) as the study cohort. For an accurate diagnosis of 
CHB, the patients who received at least 3 diagnoses during 
outpatient visits or who were admitted to a hospital with a 
primary diagnosis of CHB within the observational period 
were selected. The index event was defined as the first 
attack of CHB. Thereafter, among all subjects we enrolled 
only those who applied for a CIC due to the accompanying 
LC. In Taiwan, insured residents with major diseases (eg, 
cancer, chronic mental illness, end-stage renal disease, 
several autoimmune diseases) can apply for the CIC card 
and are not required to make copayments when seeking 
healthcare for catastrophic illness. Initially, 2181 CHB 
patients with the CIC card were recruited. However, 422 
cases were excluded because they applied for CIC for 
reasons other than LC. Additionally, patients who died or 
were followed for < 3 months after the first CHB diagnosis 
were excluded (n = 237). The outcome of interest, all-
cause mortality, was derived from CIC because an item 
within this record notes the death date if the patient has 
died. Finally, a total of 1522 subjects were included in the 
data analysis.
In Taiwan, only certified Chinese medicine 
physicians are entitled to provide CHM therapy. We 
used the frequency of visits for TCM to verify the CHM 
exposure of each study subject. Patients who received 
CHM treatment for > 30 days were considered CHM 
users,  whereas  those  who  were  treated  for  ≤  30  days 
were considered non-CHM users [[4 6]]. The index date 
of the follow-up period for those who were classified as 
non-CHM users was assigned to begin on the date of the 
first CHB diagnosis, and the index date for the follow-
up period for CHB cases with CHM use was assigned as 
the date of the initiation of CHM services. All patients 
were followed from the index date to the date of death, 
withdrawal from the insurance program, or the end of 
2012, whichever came first.
Demographic characteristics and comorbidities
Demographic characteristics evaluated in this 
study included age, sex, income for estimating insurance 
payments, and urbanization level of patients’ residential 
areas. Patients’ monthly incomes were stratified into 3 
levels: ≤ New Taiwan Dollar (NTD) 17,880, NTD 17,881–
NTD 43,900, and ≥ NTD 43,901. Urbanization levels were 
divided into 3 strata by population: urban (levels 1–2), 
suburban (levels 3–4), and rural (levels 5–7) areas. Level 
1 refers to the “most urbanized,” and level 7 refers to the 
“least urbanized” communities [29]. We also employed the 
Charlson–Deyo comorbidity index [30] to control for the 
overall disease burden of various comorbidities based on 
each study participant's medical records 1 year prior to 
cohort entry.
Statistical analysis
The characteristics of the cohort at baseline were 
compared by t-tests  and  χ2 tests. The incidence rate of 
mortality between 2 groups is the number of cases per 
1000 person–years. Hazard ratios and 95% confidence 
intervals (CI) were derived from Cox proportional hazards 
regression and met the assumption of proportionality 
of risks. To adjust for potential confounding in the 
relationship between the baseline characteristics and 
the risk of mortality, we further applied multivariate 
analysis, using Cox regression to rule out the actual effect 
of CHM on the risk of all-cause mortality. In addition, 
to test the robustness of the relation between CHM use 
and the subsequent risk of death, we divided CHM users 
into 2 subgroups: 1 group used CHM for 30–180 days, 
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and the other group used CHM for > 180 days. Kaplan–
Meier survival curves were generated for overall survival 
probability according to 2 subtypes with respect to CHM 
use. The Wilcoxon log-rank test was used to examine 
for differences. Furthermore, if an interaction of age and 
sex occurred with respect to the risk of death, a stratified 
analysis by 2 factors was conducted to more accurately 
determine the relative risk of mortality between CHM 
users and non-CHM users. All statistical analyses were 
conducted using SAS version 9.3 (SAS Institute Inc., 
Cary, NC, USA). A P value of < 0.05 was considered to 
be statistically significant.
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